Bicycle Therapeutics plc (BCYC) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-17

Business type: Asset play

What protects it: the moat

It relies on a proprietary screening platform and a unique molecule design.

Management claims the company's proprietary phage display screening platform allows it to identify molecules efficiently.

It also asserts that its Bicycle molecules are a unique therapeutic modality. This design is intended to combine the pharmacology of a biologic with the properties of a small molecule.

What growth costs

It must fund ongoing research and clinical trials to develop its drugs.

The company must invest in research and clinical trials to develop its oncology pipeline.

The filing does not state the specific amount of money required for these reinvestments.

What could damage it

If clinical trials fail, the company's core business could be permanently impaired.

The company's ability to succeed depends on its drug candidates passing clinical trials and receiving regulatory approval.

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Other companies in Biotechnology